Revolutionizing Conservation: Colossal Biosciences Seeks Funding at a $20 Billion to $30 Billion Valuation
When de-extinction startup Colossal Biosciences announced its ambitious project to ‘resurrect’ the dire wolf from genetic material found in fossils last year, the scientific community was divided. Despite the controversy surrounding the project, the company was building valuable technologies that justified its $10.2 billion valuation. Fast-forward roughly 16 months, and Colossal Biosciences is reportedly in talks to raise new funding at a staggering $20 billion to $30 billion valuation, according to Axios.
The exact details of the new funding round, including who is leading it and how much capital the company is looking to raise, remain unclear. However, one thing is certain: Colossal Biosciences has started generating revenue over the last year. According to an interview with TechCrunch last year, the company sees three revenue streams for the business:
- Conservation technology offered to governments and organizations
- Spin-off startups, including Breaking, a company that helps break down plastics, and Astromech, an AI-driven predictive modeling company focused on biology and life sciences, valued at $2 billion
- Artificial animal womb technology, which could have applications for human fertility treatment and potentially generate revenue through the sale of biodiversity credits
Colossal Biosciences has already made significant strides in this area, with the UAE investing $60 million in the company. The company has also spun out three startups, including Form Bio, a computational biology platform that secured $30 million in funding. If the company manages to reintroduce extinct animals, including the woolly mammoth and the dodo bird, to their native habitats, it may eventually generate revenue through the sale of biodiversity credits, a market-based mechanism similar to carbon credits.
The new fundraising effort comes amid a boom in longevity tech, alternative energy, and other deep-tech sectors. Colossal Biosciences’ cutting-edge technology has the potential to revolutionize the field of conservation and make a significant impact on the environment. However, the company’s ambitious goals and high valuation have raised eyebrows, and the scientific community remains divided on the ethics of de-extinction.
Ben Lamm, co-founder and CEO of Colossal Biosciences, has expressed his vision for the company’s future, stating that the artificial animal womb technology is expected to be ready next year. The company’s plans to spin off its technology and potentially generate revenue through the sale of biodiversity credits have sparked both excitement and skepticism. As the company continues to push the boundaries of what is possible, one thing is certain: Colossal Biosciences is a force to be reckoned with in the world of de-extinction and conservation technology.
